Esperion Therapeutics Inc

NASDAQ:ESPRUnited States

Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi.

Contact Information

Headquarters

601 21St Street, Suite 300VERO BEACH, FL, United States 32960

Phone

772-453-2770

Fax

302-655-5049

Executives

Independent Chairman of the Board

J. Martin Carroll

President, Chief Executive Officer, Director

Sheldon Koenig

Chief Financial Officer

Benjamin Halladay

General Counsel

Benjamin Looker

Chief Medical Officer

JoAnne Foody